Lineagen and Fast Forward Collaborate to Develop Gene and Biomarker-Based Clinical Assays for Multiple Sclerosis

Funding to Lineagen will Support Clinical Program in Collaboration with the University of Utah to Develop and Validate a Broad Array of Diagnostic and Prognostic Strategic Tools

Lineagen Launches FirstStep^Dx Genetic Testing and Counseling Service to Help Physicians Diagnose Autism and Developmental Delay Earlier

• FirstStep^Dx genetic testing and counseling service empowers physicians with tools to enhance and accelerate the diagnostic evaluation of children with indications of autism spectrum disorders (ASD) or developmental delay (DD)
• ASD is the fastest-growing neurodevelopmental disability in the U.S., affecting approximately 1 in 110 children, including up to 1 in 58 boys
• FirstStep^Dx employs advanced standard of care technology combined with genetic counseling and consultative services
• Families describe ‘life-changing’ impact of FirstStep^Dx

Lineagen CEO Michael Paul to Present Series B Update and Accelerated Demand for Genetic Testing and Counseling Services at 2011 Biotech Showcase

• Supported by key medical organization recommendation, Lineagen genetic testing and counseling services are experiencing strong demand from physicians
• Company to present an update of its current $15 Million Series B funding round
• Third annual Biotech Showcase is anticipated to attract 800 top investment and industry leaders

Lineagen, Inc. to Showcase $15 Million Series ‘B’ Round at the 9th Annual BIO Investor Forum

Lineagen Looks to Close $10 Million of New Commitments in Addition to $5 Million by Current Series ‘A’ Investors, Sanderling Ventures, vSpring Capital, PrairieGold Venture Partners and Mesa Verde Venture Partners

Lineagen, Inc. Selected to Present at the 2010 Genetic Risk Factors for Autism: Translating Discoveries into Diagnostics Symposium in Toronto

Dr. Michael S. Paul, the Company’s President & Chief Executive Officer, was selected to present at the “Genetic Risk Factors for Autism: Translating Discoveries into Diagnostics” symposium.

M-CHAT.org launched by Lineagen to accelerate in-office M-CHAT screening of children for signs of Autism Spectrum Disorders

Lineagen, Inc. announces M-CHAT.org, the first fully automated, online version of the Modified Checklist for Autism in Toddlers (M-CHAT), as a new community tool to help families and physicians make the autism screening process more efficient.

Lineagen, Inc. Announces Burt De Mill to Lead Commercial Team

Burt De Mill, formerly Senior Vice President Sales & Marketing at Genoptix Medical Laboratories, joins Lineagen to lead commercial expansion of diagnostic services for Autism Spectrum Disorders.

Lineagen, Inc. Closes $5 Million to Complete $10.8 Million Series A Round

New Investor PrairieGold Venture Partners Joins Existing Institutional Investor Line-up of Sanderling Ventures, vSpring Capital and Mesa Verde Venture Partners